Literature DB >> 11743657

Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer.

L Boldrini1, P Faviana, S Gisfredi, D Di Quirico, M Lucchi, A Mussi, C A Angeletti, F Baldinotti, A Fogli, P Simi, F Basolo, F Pingitore, G Fontanini.   

Abstract

Fas (APO-1/CD95) is a broadly expressed death receptor involved in a series of physiological and pathological apoptotic processes. One of the possible mechanisms for resistance to apoptosis signaling in the immune system as well as in the pathogenesis of non-lymphoid malignancies is the presence of Fas mutations within the entire gene. We investigated, in 79 non-small cell lung cancer (NSCLC) samples, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing in order to detect putative alterations. Sixteen of 79 tumor samples (20.2%) were found to have Fas alterations, either in promoter or exon region. Since the loss of Fas apoptotic function might be linked to p53 alterations, which are often involved in the development of NSCLC, we analyzed p53 status in 40 of the 79 NSCLC samples. p53 mutations were found to be more frequently present than Fas gene alterations (25 out of 40 cases, 62.5%). These data increase the knowledge regarding mutations of apoptosis-genes involved in the pathogenesis of NSCLC, and give benefits for the clinical management of this type of tumor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11743657     DOI: 10.3892/ijo.20.1.155

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.

Authors:  Na-Hye Myong
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

2.  Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.

Authors:  Yin Li; Ke-Ping Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.

Authors:  Andrew M Gravett; Angus G Dalgleish; John Copier
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.